NASDAQ:NVCR - NovoCure Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $195.71
  • Forecasted Upside: -13.24 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$225.58
▲ +1.15 (0.51%)

This chart shows the closing price for NVCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NovoCure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVCR

Analyst Price Target is $195.71
▼ -13.24% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for NovoCure in the last 3 months. The average price target is $195.71, with a high forecast of $250.00 and a low forecast of $142.00. The average price target represents a -13.24% upside from the last price of $225.58.

This chart shows the closing price for NVCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in NovoCure. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 2 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 2 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2021WedbushReiterated RatingNeutral ➝ Underperform$159.00 ➝ $154.00Low
4/19/2021TruistBoost Price Target$132.00 ➝ $142.00Medium
4/19/2021Truist SecuritiesBoost Price TargetHold$132.00 ➝ $142.00Low
4/14/2021Northland SecuritiesBoost Price TargetOutperform$200.00 ➝ $250.00Medium
4/14/2021WedbushDowngradeNeutral ➝ Underperform$159.00 ➝ $154.00Medium
4/14/2021MizuhoBoost Price TargetPositive ➝ Buy$175.00 ➝ $242.00Medium
4/13/2021Wells Fargo & CompanyBoost Price TargetPositive ➝ Equal Weight$135.00 ➝ $215.00High
3/1/2021MizuhoBoost Price TargetBuy$150.00 ➝ $175.00Low
1/29/2021TruistBoost Price Target$118.00 ➝ $132.00Low
1/25/2021Piper SandlerBoost Price TargetOverweight$140.00 ➝ $225.00Low
1/12/2021WedbushBoost Price Target$110.00 ➝ $159.00Medium
10/30/2020MizuhoBoost Price TargetBuy$84.00 ➝ $150.00Low
10/29/2020Piper SandlerBoost Price TargetOverweight$125.00 ➝ $140.00Medium
9/23/2020Northland SecuritiesInitiated CoverageOutperformLow
9/18/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$116.00High
9/17/2020Piper SandlerBoost Price Target$89.00 ➝ $125.00Low
9/17/2020TruistDowngradeBuy ➝ Hold$108.00High
8/3/2020SunTrust BanksReiterated RatingBuyMedium
7/31/2020WedbushReiterated RatingNeutralLow
7/31/2020MizuhoBoost Price TargetBuy$82.00 ➝ $84.00Medium
7/30/2020OppenheimerReiterated RatingHoldMedium
7/30/2020Piper SandlerBoost Price Target$85.00 ➝ $89.00Low
7/6/2020MizuhoReiterated RatingBuy$82.00Medium
6/1/2020OppenheimerInitiated CoverageBuyLow
5/27/2020MizuhoReiterated RatingBuy$82.00High
5/1/2020SunTrust BanksLower Price TargetBuy$105.00 ➝ $90.00High
5/1/2020WedbushLower Price TargetNeutral$80.00 ➝ $78.00High
5/1/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
5/1/2020OppenheimerReiterated RatingOutperform ➝ Market Perform$102.00 ➝ $78.00High
4/19/2020Piper SandlerInitiated CoverageOverweight$85.00High
4/19/2020Evercore ISIDowngradeIn-Line ➝ UnderperformHigh
4/9/2020Evercore ISIDowngradeIn-Line ➝ Underperform$75.00 ➝ $58.00Medium
4/8/2020MizuhoLower Price TargetBuy$91.00 ➝ $82.00High
4/7/2020Piper SandlerInitiated CoverageOverweight$85.00High
4/7/2020Wells Fargo & CompanyLower Price TargetOverweight$90.00 ➝ $82.00High
3/5/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$85.00 ➝ $90.00Low
2/28/2020MizuhoReiterated RatingBuy$91.00High
1/14/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
1/7/2020MizuhoReiterated RatingBuy$91.00High
12/12/2019Wells Fargo & CompanyBoost Price Target$75.00 ➝ $85.00High
11/4/2019JPMorgan Chase & Co.Reiterated RatingHold$79.00High
9/13/2019OppenheimerBoost Price TargetBuy$85.00 ➝ $97.00Low
7/29/2019SunTrust BanksUpgradeHold ➝ BuyMedium
7/26/2019OppenheimerSet Price TargetBuy$85.00N/A
7/26/2019WedbushDowngradeOutperform ➝ Neutral$57.00 ➝ $80.00High
7/26/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$61.00 ➝ $79.00High
7/26/2019MizuhoBoost Price TargetBuy$63.00 ➝ $91.00High
7/19/2019OppenheimerSet Price TargetBuy$76.00Medium
6/28/2019OppenheimerInitiated CoverageOutperform$75.00 ➝ $75.00High
5/26/2019JPMorgan Chase & Co.Reiterated RatingBuyMedium
5/24/2019WedbushReiterated RatingOutperform$57.00High
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Hold$50.00High
3/7/2019MizuhoReiterated RatingBuy$63.00Low
2/28/2019Wells Fargo & CompanyReiterated RatingHoldHigh
12/6/2018MizuhoReiterated RatingBuy$51.00Low
11/15/2018MizuhoReiterated RatingBuy$51.00Low
11/2/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformMedium
11/1/2018MizuhoReiterated RatingBuy$51.00Medium
10/30/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Market Perform$41.00 ➝ $36.00Medium
10/26/2018WedbushBoost Price TargetOutperform$55.00 ➝ $58.00Medium
10/19/2018MizuhoReiterated RatingBuy$58.00High
9/20/2018Deutsche Bank AktiengesellschaftSet Price TargetHold$44.00Low
9/19/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Positive$53.00 ➝ $58.00High
9/16/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
9/13/2018Wells Fargo & CompanyReiterated RatingBuyLow
9/7/2018WedbushReiterated RatingOutperform$50.00 ➝ $40.00High
9/6/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $48.00High
9/6/2018MizuhoReiterated RatingBuy$58.00High
7/27/2018WedbushBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $40.00Low
7/27/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $44.00High
7/25/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
7/16/2018Evercore ISIInitiated CoverageOutperform$46.00High
6/13/2018MizuhoReiterated RatingBuy$32.00Low
4/27/2018WedbushBoost Price TargetOutperform ➝ Outperform$29.00 ➝ $33.00Low
4/19/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$23.80 ➝ $19.00Low
4/18/2018MizuhoReiterated RatingBuy ➝ Buy$28.00 ➝ $32.00High
2/23/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$22.00 ➝ $19.00High
2/23/2018MizuhoReiterated RatingBuy ➝ Buy$25.00 ➝ $28.00High
12/1/2017MizuhoReiterated RatingBuy$25.00High
11/20/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/27/2017WedbushReiterated RatingOutperform$29.00 ➝ $25.00N/A
9/6/2017MizuhoInitiated CoverageBuy$25.00Medium
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$18.00 ➝ $19.00Low
5/24/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$15.00High
5/1/2017JPMorgan Chase & Co.Reiterated RatingBuy$14.00High
4/28/2017Deutsche Bank AktiengesellschaftBoost Price TargetHold$10.00 ➝ $11.00Low
4/27/2017WedbushReiterated RatingOutperform$20.00Low
4/18/2017AegisReiterated RatingBuy$14.00Low
4/7/2017WedbushReiterated RatingOutperform$20.00Low
4/4/2017JMP SecuritiesReiterated RatingOutperform$34.00High
3/28/2017AegisReiterated RatingBuy$14.00High
2/26/2017JPMorgan Chase & Co.Reiterated RatingBuy$14.00N/A
1/11/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
1/11/2017WedbushReiterated RatingOutperform$20.00N/A
12/21/2016WedbushReiterated RatingOutperform$20.00N/A
12/13/2016WedbushReiterated RatingOutperform$20.00N/A
11/18/2016WedbushReiterated RatingOutperform$20.00N/A
11/2/2016JPMorgan Chase & Co.Set Price TargetBuy$14.00N/A
7/29/2016JPMorgan Chase & Co.Lower Price TargetOverweight$29.00 ➝ $14.00N/A
7/29/2016JMP SecuritiesLower Price TargetMarket Outperform$43.00 ➝ $34.00N/A
7/29/2016Deutsche Bank AktiengesellschaftLower Price TargetHold$28.00 ➝ $16.00N/A
7/29/2016BarclaysLower Price TargetUnderweight$12.00 ➝ $9.00N/A
7/29/2016WedbushLower Price TargetOutperform$30.00 ➝ $20.00N/A
7/6/2016WedbushReiterated RatingOutperform$30.00N/A
(Data available from 6/23/2016 forward)
NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Read More

Today's Range

Now: $225.58
Low: $223.95
High: $227.66

50 Day Range

MA: $200.74
Low: $173.04
High: $225.58

52 Week Range

Now: $225.58
Low: $55.40
High: $228.10

Volume

441,996 shs

Average Volume

886,851 shs

Market Capitalization

$23.33 billion

P/E Ratio

2,050.91

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of NovoCure?

The following sell-side analysts have issued stock ratings on NovoCure in the last year: Mizuho, Northland Securities, Oppenheimer Holdings Inc., Piper Sandler, SunTrust Banks, Inc., TheStreet, Truist, Truist Securities, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NVCR.

What is the current price target for NovoCure?

7 Wall Street analysts have set twelve-month price targets for NovoCure in the last year. Their average twelve-month price target is $195.71, suggesting a possible downside of 12.8%. Northland Securities has the highest price target set, predicting NVCR will reach $250.00 in the next twelve months. Truist has the lowest price target set, forecasting a price of $142.00 for NovoCure in the next year.
View the latest price targets for NVCR.

What is the current consensus analyst rating for NovoCure?

NovoCure currently has 1 sell rating, 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVCR, but not buy more shares or sell existing shares.
View the latest ratings for NVCR.

What other companies compete with NovoCure?

How do I contact NovoCure's investor relations team?

NovoCure's physical mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider's listed phone number is 44-0-15-3475-6700 and its investor relations email address is [email protected] The official website for NovoCure is www.novocure.com.